Study wrapper · #922
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V High blood pressure & cardiovascular prevention. 2026.
DOI: 10.1007/s40292-026-00812-6PubMed: 42371360
Editor's note
This meta-analysis pools randomized controlled trials, giving it relatively strong evidentiary weight for retatrutide's cardiometabolic effects. It reports consistent reductions in blood pressure and atherogenic lipids, with heterogeneity noted for cholesterol outcomes. Findings are association-based from a drug still under clinical development.
Plain-language abstract
A meta-analysis of randomized trials found retatrutide was associated with lower systolic and diastolic blood pressure and reduced total cholesterol, LDL cholesterol, and triglycerides, with no significant change in HDL.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026